Pylarify
Ended Awarded Last action
- Contract number
- 36C24824N1004
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 8
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $14,435
Award facts
- Contract value 1% obligated
-
- $14,434.88 Current, with exercised options
- $2,540,538.88 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$93,827 | |
| Original award | $108,262 |
About this award
This federal contract award is for the delivery of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The prime contractor is Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc. that specializes in innovative diagnostic imaging agents and targeted therapies for oncology.
The contract, valued at $2,540,538.88, was awarded by the Veterans Integrated Service Network 8 (VISN 8), part of the Department of Veterans Affairs (VA). It is a Blanket Purchase Agreement (BPA) call on the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The contract has a period of performance through September 30, 2024 and is a firm fixed price arrangement. While the award is not set aside, Progenics Pharmaceuticals does hold some small business set-aside federal contract vehicles for the delivery of PYLARIFY and other radiopharmaceuticals to various government healthcare providers, including the VA, Defense Health Agency, and National Institutes of Health.
Quick answers
Who was awarded contract 36C24824N1004?
36C24824N1004 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 8 (Veterans Health Administration) on August 1, 2024.
How much is contract 36C24824N1004 worth?
The government has obligated $14,435 on 36C24824N1004. Its potential value, with all options, is $2,540,539.
Is contract 36C24824N1004 an order under another contract?
Yes. 36C24824N1004 is a BPA call under 36F79719D0170-36C24824A0038, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24824N1004 competed?
The extent of competition for 36C24824N1004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award